Back to today’s briefing

Story perspectives

Novo Nordisk Shares Plunge After Failed Alzheimer's Trial

11/24/2025

25 5

Summary

Story summary

Novo Nordisk A/S shares fell to a four-year low, dropping over 12% initially after its Alzheimer's trial failed to meet its primary endpoint.
The trial tested semaglutide, a key ingredient in Novo Nordisk's diabetes and weight-loss drugs, and found no delay in cognitive decline.
Rival Eli Lilly and Company saw its stock rise slightly, illustrating the competitive landscape as Novo Nordisk cut guidance multiple times this year.

1 of 1

Story summary

Novo Nordisk A/S shares fell to a four-year low, dropping over 12% initially after its Alzheimer's trial failed to meet its primary endpoint.
The trial tested semaglutide, a key ingredient in Novo Nordisk's diabetes and weight-loss drugs, and found no delay in cognitive decline.
Rival Eli Lilly and Company saw its stock rise slightly, illustrating the competitive landscape as Novo Nordisk cut guidance multiple times this year.